FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136462> ?p ?o ?g. }

• W4324136462 endingPage "121" @default.
• W4324136462 startingPage "121" @default.
• W4324136462 abstract "121 Background: SBRT in high risk (HR), node positive (N+) and oligometastatic (OM) prostate cancers is limited by pelvic nodal coverage, larger treatment volumes and use of hormone therapy. We report the safety, efficacy and patient reported quality of life measures (QOL) for SIB-SBRT for prostate and pelvic nodal treatment in HR, N+ and OM (non-regional node or skeletal deposits) cohorts. Methods: 22 patients of NCCN category HR, N+, OM adenocarcinoma prostate and all staged by MRI prostate and PSMA PETCT scan received SIB-SBRT from April 2019 to October 2021. All received long term androgen (ADT) deprivation therapy (80%) or surgical castration (20%). ADT was neo-adjuvant, concomitant and adjuvant for at least 2 years and for OM 2nd generation hormone treatment. SIB-SBRT to prostate and pelvic nodal regions (until common iliac level) was 35-36.25 Gy and 25 Gy in 5 fractions respectively. Post ADT gross PSMA avid nodes and skeletal deposits received 30 Gy in 5 fractions. SIB-SBRT was by volumetric modulated arc therapy (VMAT) with intrafraction imaging and hexapod robotic couch corrections on alternate days. Baseline IPSS and Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) QOL recorded and then post SIB-SBRT at 6 weeks and then 3 monthly till 2 years. Dosimetry followed standard published literature. Results: 22 patients were treated over 3 years with median age of 70 years. The median PSA at baseline was 45ng/ml with 90% Gleason score 8+. The OM disease included nonregional nodes or 1-2 skeletal deposits. After median follow up of 20 months acute grade 2 genitourinary (GU) and gastrointestinal (GI) toxicities were 10% and 12%, respectively. Late grade 2 GU and GI toxicities were 4% and 9%, respectively. Late grade 3 GU and GI toxicity was seen in 2 patients each requiring medical management. 2- year overall survival and biochemical failure-free survival was 95% and 90% respectively. Baseline median IPSS score was 9 and median EPIC CP score was 12/60. Mean urinary incontinence domain scores worsened significantly from baseline to 6 months and obstructive scores improved from baseline to 6 months with more than 95% patients not using any pads at 6 months. Bowel frequency scores were maximum at 6 weeks post SBRT and it persisted till 6 months. Sexual function scores declined gradually and recovered only in a few at last follow up. Vitality/hormonal scores were unchanged from baseline till 6 months. Conclusions: SIB-SBRT for HR, N+ and OM prostate cancers is safe and effective, with good QOL. The encouraging PSA control and minimal grade 3 toxicity and favorable therapeutic ratio achieved reflect the feasibility of LINAC based SIB-SBRT. This warrants long term follow-up with effective bladder/rectal protocol measures and optimal use of ADT in a prospective setting." @default.
• W4324136462 created "2023-03-15" @default.
• W4324136462 creator A5011961509 @default.
• W4324136462 creator A5014642665 @default.
• W4324136462 creator A5031589183 @default.
• W4324136462 creator A5068489345 @default.
• W4324136462 creator A5071178973 @default.
• W4324136462 creator A5075345820 @default.
• W4324136462 creator A5075573544 @default.
• W4324136462 creator A5080623209 @default.
• W4324136462 creator A5089816802 @default.
• W4324136462 date "2023-02-20" @default.
• W4324136462 modified "2023-09-26" @default.
• W4324136462 title "Simultaneous integrated boost (SIB) stereotactic body radiotherapy (SBRT) for prostate and pelvic nodes in high risk, node positive and oligometastatic prostate cancers: Safety, efficacy and quality of life outcome measures." @default.
• W4324136462 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.121" @default.
• W4324136462 hasPublicationYear "2023" @default.
• W4324136462 type Work @default.
• W4324136462 citedByCount "0" @default.
• W4324136462 crossrefType "journal-article" @default.
• W4324136462 hasAuthorship W4324136462A5011961509 @default.
• W4324136462 hasAuthorship W4324136462A5014642665 @default.
• W4324136462 hasAuthorship W4324136462A5031589183 @default.
• W4324136462 hasAuthorship W4324136462A5068489345 @default.
• W4324136462 hasAuthorship W4324136462A5071178973 @default.
• W4324136462 hasAuthorship W4324136462A5075345820 @default.
• W4324136462 hasAuthorship W4324136462A5075573544 @default.
• W4324136462 hasAuthorship W4324136462A5080623209 @default.
• W4324136462 hasAuthorship W4324136462A5089816802 @default.
• W4324136462 hasConcept C121608353 @default.
• W4324136462 hasConcept C126322002 @default.
• W4324136462 hasConcept C126894567 @default.
• W4324136462 hasConcept C143998085 @default.
• W4324136462 hasConcept C159110408 @default.
• W4324136462 hasConcept C2776235491 @default.
• W4324136462 hasConcept C2777008409 @default.
• W4324136462 hasConcept C2777899217 @default.
• W4324136462 hasConcept C2779384505 @default.
• W4324136462 hasConcept C2779466945 @default.
• W4324136462 hasConcept C2779951463 @default.
• W4324136462 hasConcept C2780192828 @default.
• W4324136462 hasConcept C71924100 @default.
• W4324136462 hasConceptScore W4324136462C121608353 @default.
• W4324136462 hasConceptScore W4324136462C126322002 @default.
• W4324136462 hasConceptScore W4324136462C126894567 @default.
• W4324136462 hasConceptScore W4324136462C143998085 @default.
• W4324136462 hasConceptScore W4324136462C159110408 @default.
• W4324136462 hasConceptScore W4324136462C2776235491 @default.
• W4324136462 hasConceptScore W4324136462C2777008409 @default.
• W4324136462 hasConceptScore W4324136462C2777899217 @default.
• W4324136462 hasConceptScore W4324136462C2779384505 @default.
• W4324136462 hasConceptScore W4324136462C2779466945 @default.
• W4324136462 hasConceptScore W4324136462C2779951463 @default.
• W4324136462 hasConceptScore W4324136462C2780192828 @default.
• W4324136462 hasConceptScore W4324136462C71924100 @default.
• W4324136462 hasIssue "6_suppl" @default.
• W4324136462 hasLocation W43241364621 @default.
• W4324136462 hasOpenAccess W4324136462 @default.
• W4324136462 hasPrimaryLocation W43241364621 @default.
• W4324136462 hasRelatedWork W1979955543 @default.
• W4324136462 hasRelatedWork W1982508997 @default.
• W4324136462 hasRelatedWork W2042143271 @default.
• W4324136462 hasRelatedWork W2127440557 @default.
• W4324136462 hasRelatedWork W2969214722 @default.
• W4324136462 hasRelatedWork W4281959228 @default.
• W4324136462 hasRelatedWork W4286561766 @default.
• W4324136462 hasRelatedWork W4308148977 @default.
• W4324136462 hasRelatedWork W4319948108 @default.
• W4324136462 hasRelatedWork W83392053 @default.
• W4324136462 hasVolume "41" @default.
• W4324136462 isParatext "false" @default.
• W4324136462 isRetracted "false" @default.
• W4324136462 workType "article" @default.